Tags : Bevacizumab (CT-P16)

Celltrion’s Bevacizumab Biosimilar (CT-P16) Enters into Global Phase III Clinical

Vartika Singh August 10, 2018

Shots: • Celltrion has completed Phase I on safety and efficacy of CT-P16 in June 18 • CT-P16 extended to Phase III as planned by submission […]readmore

Tags : Bevacizumab (CT-P16)

Celltrion’s Bevacizumab Biosimilar (CT-P16) Enters into Global Phase III Clinical

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Bevacizumab (CT-P16)

Celltrion’s Bevacizumab Biosimilar (CT-P16) Enters into Global Phase III Clinical

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company